Maravai LifeSciences (MRVI) announced that Rajesh Asarpota has been appointed executive VP and CFO, effective June 30. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition. Asarpota most recently served as EVP and CFO at Augmedics. The company said, “As previously communicated during the announcement of Mr. Brust’s appointment as CEO, Maravai is not reaffirming or withdrawing its full-year 2025 financial guidance at this time. The company will review its outlook during its second-quarter 2025 earnings call in August following a comprehensive business review by Mr. Brust and Mr. Asarpota.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences participates in a conference call with Jefferies
- Maravai Lifesciences Appoints Bernd Brust as New CEO
- Maravai Lifesciences appoints Bernd Brust as CEO
- TriLink BioTechnologies, Quantoom Biosciences sign license, supply agreement
- Maravai Lifesciences Holds Annual Shareholders Meeting